PT  - JOURNAL ARTICLE
AU  - AVANI ATHAUDA
AU  - DAVID WATKINS
AU  - KABIR MOHAMMED
AU  - IAN CHAU
AU  - NAUREEN STARLING
AU  - SHEELA RAO
AU  - DIANA TAIT
AU  - KATHARINE AITKEN
AU  - DAVID CUNNINGHAM
TI  - Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre
AID  - 10.21873/anticanres.12940
DP  - 2018 Oct 01
TA  - Anticancer Research
PG  - 5943--5949
VI  - 38
IP  - 10
4099  - http://ar.iiarjournals.org/content/38/10/5943.short
4100  - http://ar.iiarjournals.org/content/38/10/5943.full
SO  - Anticancer Res2018 Oct 01; 38
AB  - Background/Aim: Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and outcomes of patients treated with either cisplatin or carboplatin based CRT at our institution. Materials and Methods: This is a retrospective analysis of patients with localised OG cancer undergoing CRT with cisplatin/fluoropyrimidine (CX/F) or carboplatin/fluoropyrimidine (CarboX/F) between January 2001 and December 2014. Results: A total of 91 eligible patients were included. Median age was 65 years (IQR=57-75) for CX/F and 77 years (IQR=69-80) for CarboX/F. Adenocarcinoma histology and Charlson comorbidity index were higher in the CarboX/F group. Endoscopic complete response (CR) was achieved in 64% of CX/F group and 48% of CarboX/F group (p=0.19). The median PFS for CX/F was 31.0 months (95%CI=18.2-NE) vs. 18.7 months for CarboX/F (95%CI=13.5-30.4; HR=1.49, p=0.21). Conclusion: Despite significant differences in baseline clinical characteristics, patients treated with carboplatin CRT demonstrated no significant difference in PFS or endoscopic CR rate, compared to those treated with cisplatin.